Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValbiotisXPAR:ALVAL -0.24%50 3-Year EBITDA Growth Rate is 25.70% as of Dec. 2025, which is 140% above its 10-year median of 10.70. GuruFocus rates XPAR:ALVAL with a GF Score™ of 50/100 and a GF Value™ of €1.45 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,661 Consumer Packaged Goods companies, Valbiotis ranks better than 75.98% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Valbiotis was 25.70% per year. The lowest was -80.50% per year. And the median was 10.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Valbiotis 3-Year EBITDA Growth Rate Related Terms
XPAR:ALVAL vs KHC, GIS: 3-Year EBITDA Growth Rate Comparison
For the Packaged Foods subindustry, Valbiotis's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis 3-Year EBITDA Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Valbiotis's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.70% mean?
Valbiotis (XPAR:ALVAL) has a 3-Year EBITDA Growth Rate of 25.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Valbiotis and its competitors. This is 140% above median its historical median of 10.70. According to the industry distribution chart, Valbiotis ranks #399 out of 1661 companies in the Consumer Packaged Goods industry, placing it in the top 24%.
Is Valbiotis' 3-Year EBITDA Growth Rate too high?
Valbiotis' current 3-Year EBITDA Growth Rate of 25.70% is 140% above median its 10-year median of 10.70. The Consumer Packaged Goods industry median 3-Year EBITDA Growth Rate is 8.00. Valbiotis' value of 25.70% is 221.3% above this industry median. Based on the distribution chart, Valbiotis ranks #399 out of 1661 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Valbiotis has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' 3-Year EBITDA Growth Rate compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #399 out of 1661 companies for 3-Year EBITDA Growth Rate. This places Valbiotis in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.00. Valbiotis' value of 25.70% is 221.3% above this benchmark. While the company's 10-year median is 10.70 vs. the industry median of 8.00, Valbiotis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Consumer Packaged Goods company?
The median 3-Year EBITDA Growth Rate among Consumer Packaged Goods companies is 8.00, based on 1,661 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valbiotis's current 3-Year EBITDA Growth Rate of 25.70% is 221.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Valbiotis and its competitors. For the Consumer Packaged Goods industry, the median 3-Year EBITDA Growth Rate is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current 3-Year EBITDA Growth Rate is 25.70%, which is 140% above median its own 10-year median of 10.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.45, compared to a current price of €0.82 — trading 43.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 25.70%, which is 140% above median its 10-year median of 10.70 and 221.3% above the Consumer Packaged Goods industry median of 8.00. Valbiotis' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current 3-Year EBITDA Growth Rate is 25.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.82 is trading 43.3% below its estimated GF Value™ of €1.45.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
3-Year EBITDA Growth Rate: 25.70% (140% above median its 10-year median of 10.70)
GF Value™: €1.45 vs. price of €0.82 (43.3% below fair value)
Industry Position: 221.3% above the Consumer Packaged Goods median (#399 of 1661)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
50GF Score
Get the complete analysis for XPAR:ALVAL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
